The Weight Is Coming Off, But Is Health Improving?

GLP-1 medicines and the health measures that deserve attention alongside the scales

A worthwhile health review considers food, strength and daily life alongside weight.

Losing weight can be a welcome achievement. It can make movement easier and improve important health risks. Yet I believe we do people a disservice when a falling number on the scales becomes the main measure of their wellbeing.

A person deserves to know whether they are eating adequately, maintaining strength and receiving a plan they can sustain. Those questions matter when someone uses a GLP-1 medicine, and they matter when someone loses weight through any other approach.

My concern is the narrowness of care that can develop when appetite suppression becomes the centre of the conversation. An effective prescription still needs a thoughtful health plan around it.

Recognising the benefits honestly

There is good evidence that these medicines can improve more than appearance. In the SELECT randomised trial, 17,604 adults with overweight or obesity and established cardiovascular disease, without diabetes, received semaglutide or placebo. Major cardiovascular events occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over an average follow-up of about 40 months. That represents a 20% relative reduction and a 1.5 percentage-point absolute difference. These findings apply to that particular high-risk population; they should not be presented as the expected benefit for every user. [1]

Tirzepatide, commonly discussed alongside GLP-1 medicines, acts on both GIP and GLP-1 receptors. Different medicines and doses have different evidence. We should resist sweeping claims about the whole group, whether enthusiastic or critical.

Acknowledging benefits strengthens the case for better care. Readers deserve accurate information about both the treatment and the support needed around it.

What the scales cannot tell us

Body weight does not reveal how much someone eats, whether meals contain enough nourishment, or how comfortably they manage everyday tasks. Nor does it tell us whether a person feels able to keep going when work, illness or family pressures interrupt their routine.

The prospective SEMALEAN study illustrates why different measurements matter. Adults receiving semaglutide had an early reduction in lean mass alongside improved handgrip strength. Because it was observational and uncontrolled, it cannot establish causation. It does show why body composition and function need separate attention. [2]

That finding is a reason to ask better questions, rather than assuming either that every kilogram lost is beneficial or that all lean-mass reduction is harmful.

A broader health review

I would like patients and their health professionals to agree on a small set of meaningful measures at the start of treatment. The following is a discussion framework, not a diagnostic checklist:

· Medical outcomes: review blood pressure, glucose control and other relevant risks with the treating clinician.

· Food intake: look at what is actually being eaten across several days, including meals missed because of nausea or lack of appetite.

· Strength and function: discuss getting out of a chair, carrying groceries, climbing steps and any change in balance or confidence.

· Daily wellbeing: ask about energy, sleep, digestive symptoms and the ability to participate in family and community life.

· Sustainability: agree on follow-up, affordability and what to do if treatment is interrupted.

A 2025 joint advisory from four professional societies recommends nutritional and lifestyle assessment alongside GLP-1 treatment. Its priorities include dietary adequacy, muscle function and appropriate support. It is expert guidance informed by research, rather than a trial proving that one particular support program works. [3]

This wider review should be proportionate. Everyone does not need repeated body scans or an expensive collection of tests. A clinician can decide which measures are useful for an individual's age, symptoms and medical circumstances.

Movement has its own value

Physical activity deserves attention even when weight loss is already happening. The World Health Organization identifies benefits for cardiovascular health, physical function, mental health and sleep. It also emphasises that some activity is better than none. [4]

For someone who has been inactive, a realistic starting point may be short walks, a suitable exercise class or advice about moving safely with painful joints. The aim is to build a routine the person can maintain. Comparing themselves with someone younger or fitter rarely helps.

I would also like the consultation to distinguish walking and general activity from exercises that specifically challenge muscles. The third article in this series will examine strength in more detail.

Long-term treatment needs a long-term conversation

The US National Institute of Diabetes and Digestive and Kidney Diseases explains that weight-management medicines complement healthy eating and activity. Some people may need ongoing medication to maintain benefits. Using long-term treatment is not evidence of weak character or addiction. [5]

Equally, a person should not discover only after reaching their goal that nobody has discussed the next stage. I suggest asking early: what are we aiming to improve, when will we review progress, and what support will remain available if my circumstances change?

Those questions should not be answered with a promise that education alone will prevent weight regain. Biology, health conditions and the food environment all influence what happens next.

What I want community care to provide

As a co-founder of UltraLite, I place a high value on food education and regular support. That perspective informs my argument; it does not make these studies evidence for UltraLite itself.

I would like community pharmacies and practitioners to make room for conversations about eating, strength and practical barriers, with referral to accredited practising dietitians and suitable exercise professionals when needed. A person collecting a prescription should have an accessible route to help if their food intake becomes inadequate or everyday function deteriorates.

For readers, a useful first step is to bring one ordinary week of observations to the next appointment: what you ate, how you felt, what activities became easier and what became harder. Keep it simple. The purpose is to help you and your clinician understand your progress.

The health outcome I hope for is a person who can do more, feels supported and understands how to care for themselves. Weight is one part of that picture. It should sit within a plan that respects the whole person.

Educational information only. Discuss medication decisions and new symptoms with your treating clinician.

References

1. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389:2221-2232. doi:10.1056/NEJMoa2307563. Read the trial.

2. Alissou M et al. Impact of Semaglutide on fat mass lean mass and muscle function in patients with obesity the SEMALEAN study. Diabetes Obesity and Metabolism. 2026;28:112-121. Published online 9 October 2025. doi:10.1111/dom.70141. Read the study.

3. Mozaffarian D et al. Nutritional priorities to support GLP-1 therapy for obesity. Joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association and The Obesity Society. Obesity. 2025. doi:10.1002/oby.24336. Read the advisory.

4. World Health Organization. Physical activity. Read the guidance.

5. NIDDK. Prescription Medications to Treat Overweight and Obesity. Read the guidance.

Evidence checked 9 October 2026. Author disclosure: Malcolm McLean is a co-founder of UltraLite Weight and Health Management.